期刊
PHARMACOGENOMICS
卷 18, 期 12, 页码 1119-1123出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0054
关键词
CYP2C19; CYP3A4; inflammation; pharmacogenetics; therapeutic drug monitoring; voriconazole
How pharmacogenetics modulates the inhibitory effects of inflammation on voriconazole trough concentration (Cmin) remains unknown. In 29 recipients of allogeneic hematopoietic stem cell transplantation retrospectively studied, both a genetic score (which aggregated CYP2C19 and CYP3A genotypes) and inflammation significantly influenced voriconazole Cmin (n = 260). A trend toward (p = 0.03) a greater impact of inflammation in patients with the highest genetic score (corresponding to ultra-rapid metabolizers) was observed. Further researches are needed to confirm these data.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据